×
About 14,659,308 results

Improving Shingles Vaccination Rates in Family Medicine.
https://doi.org/10.12788/jfp.0218
The Journal of Family Practice; Luther JS

Aug 26th, 2021 - At the end of the activity, participants will be able to: • Characterize the burden of herpes zoster infections. • Recommend the recombinant zoster vaccine to patients in accordance with guidance from the Advisory Committee on Immunization Practices. • Implement strategies to increase patient acceptance of herpes zoster and other vaccinations. • Use available resources to increase awareness amo...

Alpha1-antitrypsin deficiency: New therapies on the horizon.
https://doi.org/10.1016/j.coph.2021.06.001
Current Opinion in Pharmacology; Remih K, Amzou S et. al.

Jul 14th, 2021 - Alpha1-antitrypsin deficiency (AATD) is caused by mutations in the SERPINA1 gene, coding for alpha1-antitrypsin (AAT). AAT is synthesised mainly in the liver and is released into bloodstream to protect tissues (particularly lung) with its antiprotease activity. The homozygous Pi∗Z mutation (Pi∗ZZ genotype) is the predominant cause of severe AATD. It interferes with AAT secretion thereby leading...

Central and peripheral arterial diseases in chronic kidney disease: conclusions from a ...
https://doi.org/10.1016/j.kint.2021.04.029
Kidney International; Johansen KL, Garimella PS et. al.

May 8th, 2021 - Chronic kidney disease (CKD) affects about 10% of all populations worldwide, with about 2 million people requiring dialysis. Although patients with CKD are at high risk of cardiovascular disease and events, they are often underrepresented or excluded in clinical trials, leading to important knowledge gaps about how to treat these patients. KDIGO (Kidney Disease: Improving Global Outcomes) conve...

ESMO Virtual Congress 2020: Abstracts
https://www.esmo.org/meetings/esmo-virtual-congress-2020/abstracts

Sep 19th, 2020 - Abstract submission categories Basic science Biliary tract cancer, incl. cholangiocarcinoma Biomarkers (agnostic) Breast cancer, early stage Breast cancer, locally advanced Breast cancer, metastatic CNS tumours Colorectal cancer Developmental therapeutics Endocrine tumours Genitourinary tumours, prostate Genitourinary tumours, non-prostate Gynaecological cancers Haematological mal...

ESMO Virtual Congress 2020: Program
https://www.esmo.org/meetings/esmo-virtual-congress-2020/programme

Sep 19th, 2020 - The ESMO Virtual Congress 2020 Programme is now online! The ESMO Virtual Congress 2020 will be the global stage for the exchange and debate of translational cancer science of excellence, first announcements of practice-changing data, and multidisciplinary must-have conversations set to spur transformative therapies against cancer.

Expert Perspective on ASCO20 Quality Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200237/full/

Jul 7th, 2020 - This essential study (Abstract 2003) highlights that health policy impacts cancer survival. It showed that age-adjusted mortality from cancer is worse in states that have not expanded access to Medicaid under the Affordable Care Act. There were 758 fewer cancer deaths in expansion states in 2017, and Hispanic populations had the greatest decrease in mortality under Medicaid expansion. This stud...

Expert Perspectives on the ASCO20 Plenary Session
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200236/full/

Jul 6th, 2020 - The JAVELIN Bladder 100 study (LBA1) investigated the efficacy of maintenance avelumab following platinum-based chemotherapy compared to best supportive care for patients with metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared to 14.3 months with best supportive care. These data are practice changing, and the degree of benefit to this a...

Top Lung Cancer Research Presented at the ASCO20 Virtual Scientific Program Has Implications for Clinical Practice
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200223/full/

Jun 25th, 2020 - Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, MD, of the University of North Carolina School of Medicine, reviewed the most influential lung cancer research presented during the ASCO20 Virtual Sci...

Will DFS Benefit Translate Into Survival Benefit in ADAURA?
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200221/full/

Jun 24th, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 24th, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...

Results From an Oncology Hospital-at-Home Evaluation
https://ascopost.com/news/june-2020/results-from-an-oncology-hospital-at-home-evaluation/

Jun 5th, 2020 - Researchers at Huntsman Cancer Institute (HCI) at the University of Utah presented the first outcomes evaluation of an adult oncology hospital-at-home program during the ASCO20 Virtual Scientific Program (Abstract 7000). The study evaluated patients participating in HCI's Huntsman at Home program. The data demonstrated strong evidence for the benefits of this care model, showing improved patien...

Durvalumab Added to Standard Chemotherapy Improved Overall Survival in Patients With Malignant Pleural Mesothelioma
https://ascopost.com/news/june-2020/durvalumab-added-to-standard-chemotherapy-improved-os-in-patients-with-malignant-pleural-mesothelioma/

Jun 1st, 2020 - Data from clinical efficacy and biomarker analyses conducted for the single-arm phase II PrE0505 study of the initial treatment of patients with malignant pleural mesothelioma were presented by Patrick Forde, MB, BCh, and colleagues during the Lung Cancer Oral Abstract Session at the ASCO20 Virtual Scientific Program (Abstract 9003). The trial evaluated the addition of durvalumab, an immune che...

Carfilzomib vs Bortezomib in Addition to Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma
https://ascopost.com/news/june-2020/carfilzomib-vs-bortezomib-in-addition-to-lenalidomidedexamethasone-in-newly-diagnosed-multiple-myeloma/

Jun 1st, 2020 - The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care: bortezomib, lenalidomide, and dexamethasone (VRd). Data from a planned interim analysis for efficacy and toxicity in the randomized phase III ENDURANCE trial were presented in the P...

Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management
https://ascopost.com/videos/asco20-virtual-scientific-program/michael-morris-on-the-impact-of-psma-targeted-imaging-on-clinical-management-of-prostate-cancer/

Jun 1st, 2020 - Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).

Rana R. McKay, MD, on Prostate Cancer: Intense Androgen-Deprivation Therapy Before Radical Prostatectomy
https://ascopost.com/videos/asco20-virtual-scientific-program/rana-mckay-on-intense-adt-before-radical-prostatectomy/

Jun 1st, 2020 - Rana R. McKay, MD, of the University of California, San Diego, discusses the results of a phase II trial of intense neoadjuvant hormone therapy followed by radical prostatectomy in men with high-risk prostate cancer. The data show that 21% of patients had a favorable pathologic response (Abstract 5503).

Off-the-shelf CAR-T regimen safe for advanced lymphoma
https://www.healio.com/hematology-oncology/lymphoma/news/online/{87e5706a-8ecb-4473-95b8-60f27a6e22cb}/off-the-shelf-car-t-regimen-safe-for-advanced-lymphoma

Jun 1st, 2020 - An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.

IMvigor010 Misses DFS End Point in Muscle-Invasive Urothelial Carcinoma
https://www.onclive.com/conference-coverage/asco-2020/imvigor010-misses-primary-endpoint-in-in-miuc

May 31st, 2020 - The phase 3 IMvigor010 trial comparing adjuvant atezolizumab (Tecentriq) with observation in patients with muscle-invasive urothelial carcinoma (MIUC) failed to meet its primary endpoint of disease-free survival (DFS), according to primary analysis data presented at the 2020 ASCO Virtual Scientific Program.

Final ANANOVA2 Survival Data Support Niraparib Plus Bevacizumab in Recurrent Ovarian Cancer
https://www.targetedonc.com/view/final-ananova2-survival-data-support-niraparib-plus-bevacizumab-in-recurrent-ovarian-cancer

May 31st, 2020 - Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology at Rigshopitalet–Copenhagen University Hospital in Denmark and medical director of the Nordic Society of Gynaecological Oncology, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib (Zejula) plus bevacizumab (Avastin) versus niraparib alon...

CAR T-Cell Therapy Impresses in Indolent NHL
https://www.medpagetoday.com/meetingcoverage/asco/86783

May 31st, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment
https://www.onclive.com/conference-coverage/asco-2020/cabozantinib-maintains-efficacy-in-advanced-rcc-irrespective-of-prior-treatment

May 31st, 2020 - Patients with advanced renal cell carcinoma (RCC) who were treated with the multikinase inhibitor cabozantinib (Cabometyx) following both immunotherapy (IO) and non-IO regimens demonstrated promising responses, suggesting the agent’s efficacy regardless of prior therapy, according to data from a pooled analysis of patients treated on the phase 3 METEOR (NCT01865747) and the phase 2 Japanese C20...